Literature DB >> 19774358

Insulin resistance and increased risk for malignant neoplasms: confounding of the data on insulin glargine.

J M Nagel, U Mansmann, K Wegscheider, J Röhmel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19774358     DOI： 10.1007/s00125-009-1535-0

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  6 in total

1.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.

Authors:  Wolfgang Rathmann; Guido Giani
Journal:  Diabetes Care       Date:  2004-10       Impact factor: 19.112

Review 2.  Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence.

Authors:  D LeRoith; R Novosyadlyy; E J Gallagher; D Lann; A Vijayakumar; S Yakar
Journal:  Exp Clin Endocrinol Diabetes       Date:  2008-09-05       Impact factor: 2.949

3.  Insulin glargine and malignancy: an unwarranted alarm.

Authors:  Stuart J Pocock; Liam Smeeth
Journal:  Lancet       Date:  2009-07-17       Impact factor: 79.321

4.  Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.

Authors:  P Kurtzhals; L Schäffer; A Sørensen; C Kristensen; I Jonassen; C Schmid; T Trüb
Journal:  Diabetes       Date:  2000-06       Impact factor: 9.461

5.  Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden.

Authors:  Kazem Zendehdel; Olof Nyrén; Claes-Göran Ostenson; Hans-Olov Adami; Anders Ekbom; Weimin Ye
Journal:  J Natl Cancer Inst       Date:  2003-12-03       Impact factor: 13.506

6.  Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.

Authors:  L G Hemkens; U Grouven; R Bender; C Günster; S Gutschmidt; G W Selke; P T Sawicki
Journal:  Diabetologia       Date:  2009-06-30       Impact factor: 10.122
  6 in total
  9 in total

1.  Protected graft copolymer (PGC) basal formulation of insulin as potentially safer alternative to Lantus® (insulin-glargine): a streptozotocin-induced, diabetic Sprague Dawley rats study.

Authors:  Sandra Reichstetter; Gerardo M Castillo; ManShun Lai; Akiko Nishimoto-Ashfield; Aryamitra Banerjee; Alexei Bogdanov; Alexander V Lyubimov; Elijah M Bolotin
Journal:  Pharm Res       Date:  2011-12-28       Impact factor: 4.200

2.  Insulin glargine and NPH insulin increase to a similar degree epithelial cell proliferation and aberrant crypt foci formation in colons of diabetic mice.

Authors:  Jutta M Nagel; Jürgen Staffa; Ingrid Renner-Müller; David Horst; Michael Vogeser; Markus Langkamp; Andreas Hoeflich; Burkhard Göke; Frank T Kolligs; Christos S Mantzoros
Journal:  Horm Cancer       Date:  2010-12       Impact factor: 3.869

3.  Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor.

Authors:  E Yehezkel; D Weinstein; M Simon; R Sarfstein; Z Laron; H Werner
Journal:  Diabetologia       Date:  2010-09-12       Impact factor: 10.122

4.  Intensive glucose control and risk of cancer in patients with type 2 diabetes.

Authors:  G Stefansdottir; S Zoungas; J Chalmers; A P Kengne; M J Knol; H G M Leufkens; A Patel; M Woodward; D E Grobbee; M L De Bruin
Journal:  Diabetologia       Date:  2011-04-21       Impact factor: 10.122

5.  Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients.

Authors:  Edoardo Mannucci; Matteo Monami; Daniela Balzi; Barbara Cresci; Laura Pala; Cecilia Melani; Caterina Lamanna; Ilaria Bracali; Michela Bigiarini; Alessandro Barchielli; Niccolo Marchionni; Carlo Maria Rotella
Journal:  Diabetes Care       Date:  2010-06-14       Impact factor: 17.152

6.  Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues. Reply to Nagel JM, Mansmann U, Wegscheider K et al. [letter] and Simon D [letter].

Authors:  U Grouven; L G Hemkens; R Bender; P T Sawicki
Journal:  Diabetologia       Date:  2009-10-24       Impact factor: 10.122

Review 7.  Cancer biology in diabetes.

Authors:  Shi Sen; Yanzheng He; Daisuke Koya; Keizo Kanasaki
Journal:  J Diabetes Investig       Date:  2014-03-05       Impact factor: 4.232

8.  Diabetes, glucose control, glucose lowering medications, and cancer risk: a 10-year population-based historical cohort.

Authors:  Rachel Dankner; Ran Balicer; Paolo Boffetta; Lital Keinan Boker; Sylvan Wallenstein; Laurence Freedman; Margalit Goldfracht; Jesse Roth; Ronald Tamler; Derek LeRoith
Journal:  BMC Cancer       Date:  2012-08-23       Impact factor: 4.430

Review 9.  The metabolic and mitogenic properties of basal insulin analogues.

Authors:  Norbert Tennagels; Ulrich Werner
Journal:  Arch Physiol Biochem       Date:  2013-02       Impact factor: 4.076
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.